Who this is for
This page is for people who have recently been diagnosed with early-stage breast cancer — cancer that is confined to the breast and nearby lymph nodes and has not spread to distant organs.
If you have just heard the words “you have breast cancer,” the shock can be overwhelming. The most important thing to know is this: early breast cancer is often highly treatable, and modern treatment is increasingly personalised rather than automatic.
What does “early breast cancer” mean?
Early breast cancer refers to cancer that is limited to the breast and regional lymph nodes (stage I–III) without distant metastases.
Treatment in this setting is given with curative intent.
The goal is not simply to treat — but to prevent recurrence.
The five factors that guide treatment
Modern treatment decisions are not one-size-fits-all. They are guided by:
• Tumour size
• Lymph node involvement
• Hormone receptor (ER/PR) status
• HER2 status
• Tumour biology (including genomic assays where appropriate)
Two patients with similar tumour size may require completely different treatment depending on biology.
Surgery: the first step
Most early breast cancers are treated with:
• Breast-conserving surgery (lumpectomy) plus radiation
or
• Mastectomy
Survival outcomes are equivalent when appropriately selected.
Surgery removes visible disease. The next decisions aim to reduce microscopic recurrence risk.
Do all patients need chemotherapy?
No.
Chemotherapy is no longer automatic in early breast cancer.
In hormone receptor–positive, HER2-negative disease, genomic testing can help determine who benefits and who can safely avoid chemotherapy.
When chemotherapy can be avoided (TAILORx)
TAILORx studied women with node-negative, hormone receptor–positive, HER2-negative early breast cancer.
Key findings:
• In women over 50 with intermediate recurrence scores, chemotherapy did not improve invasive disease-free survival.
• 9-year invasive disease-free survival was approximately 84–85% with endocrine therapy alone.
• Hazard ratio for chemotherapy benefit in the intermediate group: not statistically significant.
Interpretation: Many women can safely avoid chemotherapy without compromising long-term outcomes.
Node-positive disease is not all the same (RxPONDER)
RxPONDER evaluated women with 1–3 positive lymph nodes.
Key findings:
• Postmenopausal women with low genomic risk did not benefit from chemotherapy.
• Invasive disease-free survival hazard ratio: 1.02 (no significant benefit in postmenopausal group).
• Premenopausal women showed benefit from chemotherapy (hazard ratio approximately 0.60).
Interpretation: Lymph node positivity alone does not mandate chemotherapy. Biology matters.
When additional targeted therapy is recommended (monarchE)
In high-risk hormone receptor–positive disease:
monarchE studied abemaciclib plus endocrine therapy.
Key findings:
• Invasive disease-free survival hazard ratio: 0.70
• Absolute improvement in 4-year invasive disease-free survival ~6–7%
• Benefit observed in high-risk node-positive disease
Interpretation: Some early breast cancers require escalation beyond endocrine therapy alone.
HER2-positive early breast cancer
For HER2-positive disease:
• Trastuzumab-based therapy significantly improves survival
• Pathologic complete response after neoadjuvant therapy predicts excellent outcomes
• Antibody–drug conjugates are now changing outcomes in residual disease
Treatment is targeted and highly effective.
Radiation therapy
After breast-conserving surgery, radiation reduces local recurrence risk.
In selected low-risk older patients, radiation may sometimes be omitted after careful discussion.
What matters most
Early breast cancer treatment today is about balance:
• Avoiding overtreatment
• Preventing undertreatment
• Using biology to guide intensity
The goal is long-term cure with the least toxicity necessary.
Melbourne and Australia context
In Melbourne and across Australia:
• Genomic testing is routinely used in appropriate patients
• Multidisciplinary discussion is standard
• Access to targeted therapies is aligned with international guidelines
Treatment pathways mirror global best practice.
International patients, including Sri Lanka
Patients from Sri Lanka sometimes seek an Australian second opinion after early breast cancer diagnosis.
A structured review of pathology, receptor status and genomic testing can clarify whether chemotherapy is necessary and whether escalation or de-escalation is appropriate.
Early breast cancer management increasingly depends on precise interpretation — not routine escalation.
Key Takeaway
• Early breast cancer is often highly treatable and managed with curative intent.
• Chemotherapy is not automatic — genomic testing helps personalise decisions.
• Treatment intensity is guided by tumour biology, not fear.
Frequently Asked Questions
Is early breast cancer curable?
Many early breast cancers are treated with curative intent. Long-term survival rates are high, particularly when treatment is tailored to tumour biology and stage.
Do all patients with lymph node–positive breast cancer need chemotherapy?
No. Studies such as RxPONDER show that some postmenopausal women with 1–3 positive lymph nodes and low genomic risk do not benefit from chemotherapy.
What is genomic testing in early breast cancer?
Genomic testing (such as recurrence score assays) evaluates tumour biology to estimate recurrence risk and guide chemotherapy decisions in hormone receptor–positive, HER2-negative disease.
Is more treatment always better?
Not necessarily. Modern oncology focuses on delivering the right amount of treatment — enough to reduce recurrence risk without unnecessary toxicity.
Key Evidence (AMA Style)
1. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer (TAILORx). N Engl J Med. 2018;379(2):111-121.
2. Kalinsky K, Barlow WE, Meric-Bernstam F, et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer (RxPONDER). N Engl J Med. 2021;385(25):2336-2347.
3. Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for high-risk early breast cancer (monarchE). N Engl J Med. 2020;383(22):2097-2108.
4. Slamon DJ, Eiermann W, Robert NJ, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273-1283.